摘要
目的:观察中药复方糖肾宝冲剂治疗Ⅳ期糖尿病肾病(DN)的临床疗效及可能作用机制。方法:将84例Ⅳ期DN患者,按随机数字表法分为治疗组和对照组,每组各42例。对照组采用基础治疗,治疗组在对照组的基础上给予糖肾宝冲剂冲服,每日2次,疗程16周。治疗结束后,观察治疗前后两组的中医症状积分、血糖、血清肌酐(Scr)、尿白蛋白排泄率(UAER)、N-乙酰β-D氨基葡萄糖苷酶(NAG)、单核细胞趋化蛋白(MCP-1)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)等的变化。结果:(1)治疗后两组中医症状积分明显降低(P<0.01),但治疗组明显低于对照组(P<0.01)。(2)治疗前后两组血糖、Scr差异无统计学意义(P>0.05);治疗后两组UAER明显改善(P<0.01),但治疗组较对照组改善更显著(P<0.05);治疗后治疗组尿NAG显著改善(P<0.01),而对照组改善不明显(P>0.05)。(3)治疗后两组MCP-1、IL-6及TNF-α均显著改善(P<0.01,P<0.05),但治疗组较对照组改善更显著(P<0.01,P<0.05)。结论:糖肾宝冲剂能改善Ⅳ期DN患者的临床症状,减轻肾损害,其作用机制可能与抑制炎症状态有关。
Objective：To investigate the clinical efficacy and the possible action mechanism of Chinese herbal compound Tangshenbao Granules in treating the 4th stage of the Diabetic Nephropathy（DN）. Methods：84 patients in the stageⅣof DN were equally randomly divided into the treated group and the control group. Vonventiona treatment was given to all patients and the treated group was administered with Tangshenbao Granules twice a day additionally for 16 weeks. Changes of symptoms were observed,and laboratory indexes,as blood glucose,Serum Creatine（ Scr）,Urinary albumin excretion rate（ UAER）,acetylgcosamidase（ NAG）, monocyte chemoattractant protein-1（MCP-1）,inter leukin-6（IL-6）and tumor necrosis factor-α（TNF-α）were detected be-fore and after treatment. Results：（1）The symptom integral has reduced obviously in the two groups after treatment（P〈0. 01）,but the reduction was more obvious in the treat group than that in the control group（P〈0. 01）.（2）Blood glucose and SCr were no sig-nificant differences before and after treatment（P〉0. 05）;UARE was certainly improved in the two groups（P〈0. 01）,and more im-provement was achieved in the treat group than that in the control group（P〈0. 05）;NAG was significantly improved in the treat group（P〈0. 01）,while there is no obvious improvement in the treat group（P〉0. 05）.（3）MCP-1 IL-6 and TNF-αwere sig-nificantly improved in the two groups（P〈0. 01,P〈0. 05）,however the improvement was more significant in the treat group than the control group（P〈0. 01,P〈0. 05）. Conclusion：Tangshenbao Granules could improve the clinical effect of patients in the stageⅣof DN and alleviate the damage of kidney. Its action mechanism may be related to inhibit inflammation state.
出处
《中国中西医结合肾病杂志》
2014年第12期1066-1068,共3页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
广西壮族自治区卫生厅中医药科技专项项目(No.GZPT1225)
